Get started
Author

Taek Sang Kwon

Observed names: Kwon, Taek, Kwon, Taek Sang, T S Kwon, Taek Kwon, Taek S. Kwon
ORCID: 0000-0002-7766-0141
Observed ORCID: 0000-0002-7766-0141
OpenAlex ID: A5102198759
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
2016 · Dae Hyun Yoo, Chang-Hee Suh, et al. · Annals of the Rheumatic Diseases · 86
PDF
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
2020 · Roberto Caporali, Yannick Allanore, et al. · Expert Review of Clinical Immunology · 33
PDF
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
2021 · Bernard Combe, Yannick Allanore, et al. · Arthritis Research & Therapy · 19
PDF
Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
2022 · Yoram Bouhnik, Raja Atreya, et al. · Inflammatory Bowel Diseases · 9
Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
2021 · Han Geul Byun, Minyoung Jang, et al. · Applied Health Economics and Health Policy · 9
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
2024 · Laurent Peyrin‐Biroulet, Perttu Arkkila, et al. · BMC Gastroenterology · 7
PDF
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis
2025 · Bruce E. Sands, Laurent Peyrin-Biroulet, et al. · Journal of Clinical Medicine · 6
PDF
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
2022 · Arnaud Constantin, Roberto Caporali, et al. · Rheumatology · 6
Budget impact of introducing an omalizumab biosimilar in 23 European countries
2025 · Minyoung Jang, Jooyeop Lee, et al. · Journal of Medical Economics · 5
PDF
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis
2025 · Marc Ferrante, Laurent Peyrin-Biroulet, et al. · Therapeutic Advances in Gastroenterology · 1
Uncovering the full economic impact of biosimilars: a “would have spent” counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016–2025
2026 · Seungjae Yi, Minyoung Jang, et al. · Figshare
Uncovering the full economic impact of biosimilars: a “would have spent” counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016–2025
2026 · Seungjae Yi, Minyoung Jang, et al. · Journal of Medical Economics
PDF
EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab
2025 · Seungjae Yi, Minyoung Jang, et al. · Value in Health
EE109 Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries
2025 · Minyoung Jang, Joo Yeop Lee, et al. · Value in Health
Perceived benefits and cost savings of liquid formulation of intravenous infliximab: perspectives of seven European countries
2025 · Kyoungwan Nam, Taek Sang Kwon, et al. · Expert Opinion on Biological Therapy
PDF
EE513 Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab
2025 · Seungjae Yi, Minyoung Jang, et al. · Value in Health
Comparative Efficacy and Safety of Subcutaneous Infliximab and Vedolizumab Maintenance Therapy in Patients With Crohn’s Disease and Ulcerative Colitis: an Indirect Comparison From Randomized Controlled Trials
2024 · Bruce Sands, Laurent Peyrin-Biroulet, et al. · Inflammatory Bowel Diseases
PDF
Comparative Efficacy and Safety of Subcutaneous Infliximab and Vedolizumab Maintenance Therapy in Patients With Crohn’s Disease and Ulcerative Colitis: an Indirect Comparison From Randomized Controlled Trials
2024 · Bruce Sands, Laurent Peyrin-Biroulet, et al. · Gastroenterology
PDF
Sa1144 TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE PHASE OF INFLIXIMAB OR VEDOLIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
2023 · Marc Ferrante, Laurent Peyrin-Biroulet, et al. · Gastroenterology
Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
2022 · Deborah Baik, Raja Atreya, et al. · Gastroenterology
PDF
Su1516: A COMPARATIVE ANALYSIS BETWEEN INFLIXIMAB AND VEDOLIZUMAB ON PATIENTS WITH CROHN'S DISEASES AND ULCERATIVE COLITIS WHO DISCONTINUED DURING MAINTENANCE TREATMENT DUE TO LACK OF EFFICACY: META-ANALYSIS USING RANDOMIZED CONTROLLED TRIALS
2022 · Marc Ferrante, Perttu Arkkila, et al. · Gastroenterology
DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis
2022 · L Peyrin-Biroulet, P Arkkila, et al. · Journal of Crohn s and Colitis
The Efficacy of Transcatheter Arterial Embolization(TAE) in Children With Blunt Splenic Injury
1998 · Si Kyun Park, Young Ju Kim, et al. · Journal of the Korean Radiological Society
Works count: 30
Citation count: 181
H-index: 6
I10-index: 3
Year
Topic
Type